Currently there are three commercially available thrombin generation methods. These methods help detect the levels of thrombin generated in patient samples by the use of chromogenic or fluorogenic substrates in plasma or whole blood. Determining the rate of thrombin generation can help indicate if patients are at risk of clotting or bleeding.
Literature from commercial manufacturers for equipment, software packages and chemical producers were also reviewed.
| THROMBIN GENERATION METHODS
Continuous monitoring of thrombin was first introduced by Hemker et al. 1 in 1993, which laid the groundwork for what is now known as calibrated automated thrombography (CAT) in 2003. 2 Previously to this, thrombin generation assay (TGA) was a laborious, timeconsuming task that required individual time point sampling from the original sample, also known as subsampling, in order to generate a snapshot picture of thrombin formation. With a limited view by subsampling due to a small number of data points, the overall picture of thrombin generation was incomplete. 3 The introduction of the CAT protocol allowed for rapid, continuous measurement of multiple samples, greatly improving the efficiency and accuracy of the thrombin generation assay.
The advancement of the TGA led to the production of the commercially available fluorogenic thrombin assays. Since then, there has been a bifurcation in the commercial TGA into using either chromogenic or fluorogenic assays to determine the levels of thrombin in a sample, whether it be a platelet poor (PPP) or platelet rich (PRP) plasma. PPP is used frequently since it has defined concentrations of tissue factor and phospholipids in each plasma sample, allowing for easy standardization. 4 This standardization of thrombograms has resulted in three commercial automated thrombin assays and corresponding software At the most basic level, the three systems are similar in that they continuously measure the generation of thrombin via production of an indicator through the cleavage of a substrate. This reaction specifically occurs through the active site between the 60-loop and the γ-loop of thrombin.
5,6
The preparation of the plasma samples for the three systems is similar in that plasma is obtained 
| SUBSTRATES AND DATA PROCESSING
The main differences between the three systems are the use of ei- 20% to the total AUC. 13 However, in the case of fluorogenic assays there is a significant difference in the mathematical processing of the inner filter effect, also known as fluorescence quenching. Fluorescence quenching occurs when the fluorophore absorbs light generated from fluorescence. As the concentration of fluorophore increases, there is a non-linear increase in the quenching. This is tied with a continuous decrease in the substrate concentration as it is being consumed by the thrombin generated in the PPP. These two factors combine to cause a rapid decrease in the rate of change (dF/dt) in the overall fluorescence after the initial "burst" of fluorescence. Using a mathematical calculation known as an H-transform, it is possible to take the acquired data and to generate a diagnostic plot that accounts for the inner filter effect and the substrate consumption.
14 However, even with this correction there can also be quenching from various compounds in the plasma that can change from sample to sample and can in turn affect the results of the plot. 15 For the Technothrombin system there is no correction for this inner filter effect, resulting in a lower overall ETP and shorter peak height versus that of the Thombinoscope which does factor the inner filter effect into the calculations. 16 In the case of the BCS-XP there is no need for this correction as the inner filter effect only applies to fluorescence.
After the raw data are collected, the mathematical calculations 
17
Another difference between the two commercial thrombin substrates is that the fluorogenic substrate Z-Gly-Gly-Arg-AMC, uses a carboxybenzyl ('Z' or 'Cbz' in shorthand) protecting group on the Nterminus of the peptide, while the H-β-Ala-Gly-Arg-pNA ( Figure 2 ) has a free amine. Work by Berkel, et al. showed that when the carboxylbenzyl group was removed from the Z-Gly-Gly-Arg-AMC and replaced with the free amine to generate H-Gly-Gly-Arg-AMC, both the K m and k cat increased by a factor of 6 and 3, respectively. This modification also resulted in a ninefold increase in selectivity of thrombin over Factor Xa. 18 While the core of the Z-Gly-Gly-Arg-AMC and H-β-AlaGly-Arg-pNA substrates are fairly similar, it is possible that the bulkier Cbz substituent on the fluorogenic substrate is a poor fit in the active site of thrombin, leading to a significantly slower rate of hydrolysis than that of the unprotected variant.
When comparing the chromogenic to fluorogenic substrate, the kinetics are fairly similar, with the k cat /K m , being about the same (Table 2) .
However, some of the original data specify that the k cat of the fluorogenic substrate is 310 s 
| THROMBIN GENERATION IN CLINCAL SETTTINGS
In regards to the analysis that the three systems perform, there is no one system that is superior to the other and each has its own advantages and disadvantages. Currently, in regards to the three systems there are no clinical studies that directly compare the rates of thrombin generation to patient outcomes. Though the recommended detectors are not required, they are designed with the specific assays in mind, as well as being able to perform similar assays (APTT, PT, etc.).
The main advantage of the BCS system over the fluorogenic systems is the lower overall scan time, allowing for more samples per hour to be run. However, one disadvantage is that in combination with the lack of an internal standard, the concentration of thrombin cannot be directly reported for the BCS system. 22 The main advantage of the fluorogenic systems is their ability to directly quantify the exact amount of thrombin generated in a patient's plasma. The disadvantage however, is the longer amount of time required for sample analysis and the interference that can be caused by the IFE (Table 4) .
Overall the three methods are somewhat similar in sample preparation, use of substrates, and data analysis. The main issue for analysing thrombin generation is that all three methods still use very laborious preparations and a multiple to perform a test that takes many minutes to complete and cannot be done on a large, rapid scale. The lack of consistent results is a problem for the TGA, as well as the fact that results can vary from location to location, 11 with day-to-day variation also present,
despite the same individual being tested. 8 In addition, the inability of the substrates to differentiate free thrombin and α 2 M-thrombin complex in the automated assays is an issue in that the assay doesn't reflect the true levels of free thrombin, though corrections do get it closer to the actual value. This particular problem can only be solved with the design of new substrates that are selective for free thrombin.
While two of the three commercially available TGA systems attempt to correct for the presence of the α 2 M-thrombin complex, the Thombinoscope through a calibrator and the BCS system via mathematical calculations, there is a significant issue with this both approaches. The rate of α 2 M calculated for every system is constant regardless of the source. It has been shown that the levels of α 2 M can vary greatly by age, 23, 24 and by clinical conditions such as hepatitis C, 25 pancreatitis, 26 or acute ischemic heart disease. 27 However, with such a heterogeneity of α 2 M concentrations it would be nearly impossible to predict an accurate amount of α 2 M in each individual sample without exhaustive analysis. An ideal solution to this situation would be to design a substrate that could specifically detect thrombin without detecting α 2 M-thrombin complexes. This goal is particularly challenging since α 2 M-thrombin complex contains the same active site as the free thrombin that hydrolyses the available substrates. To design a substrate that could discriminate between thrombin and α 2 Mthrombin complex will require a significant amount of resources. This could lead to more consistent and physiologically relevant results by eliminating a major variable that is a part of all currently available commercial thrombin generation methods.
While the total volume of plasma is minimal and could easily be run multiple times on standard 3 mL sample of whole blood, the sam- 
| CONCLUDING REMARKS
The three commercially available thrombin generation methods can detect the continuous generation of thrombin in a patient sample.
The major differences between the methods originate from the substrates themselves, the sample preparation required for the dif- 
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